New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free

TB-500

Also known as: Thymosin Beta-4 Fragment, Thymosin Beta-4 Synthetic Analog

TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring peptide found in nearly all human and animal cells. It promotes cell migration to injury sites, accelerates tissue regeneration, and reduces chronic inflammation.

Half-Life

2–3 hours

Route

SubQ, IM

Category

Recovery & Repair

Studies

14 references

Key Benefits

  • Enhances muscle tissue regeneration
  • Accelerates healing of wounds and injuries
  • Reduces inflammation and pain
  • Improves flexibility and mobility
  • Promotes new blood vessel formation
  • Supports hair growth and skin health
  • May improve cardiac function after injury
  • Systemic healing effect — works at distance from injection site

Mechanism of Action

TB-500 is a synthetic version of Thymosin Beta-4 that promotes cell migration, differentiation, and angiogenesis by upregulating actin polymerization. This enables cells to migrate to injury sites more effectively. It also promotes new blood vessel formation, reduces inflammation, and supports tissue remodeling. The peptide upregulates G-actin, facilitating the mobility of repair cells throughout the body.

Dosing Protocols

Loading Phase

Dose
2–2.5 mg
Frequency
Twice weekly
Timing
Any time
Cycle
4–6 weeks

Loading phase to saturate tissue levels and initiate repair response.

Maintenance Phase

Dose
2–2.5 mg
Frequency
Once weekly
Timing
Any time
Cycle
Ongoing as needed

Follow loading phase; continue for ongoing healing or injury prevention.

Calculate your draw volume

Enter your vial size and BAC water to get exact injection volumes

Calculate dose →

Side Effects

  • Injection site discomfort
  • Fatigue (rare)
  • Headache (rare)

Contraindications

Active cancer or history of cancer. Pregnancy or breastfeeding. Uncontrolled cardiovascular conditions.

Storage

Lyophilized powder: store at −20°C. Reconstituted solution: refrigerate at 2–8°C, use within 30 days.

  1. 1.
    Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions

    Rahman OF, Lee SJ, Seeds WA · Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026ReviewPubMed Verified

  2. 2.
    Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians

    Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF et al. · The American journal of sports medicine · 2026ReviewPubMed Verified

  3. 3.
  4. 4.
    Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro

    Rahaman KA, Muresan AR, Min H, Son J, Han HS, Kang MJ et al. · Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2024PubMed Verified

  5. 5.
    Adsorption effects of the doping relevant peptides Insulin Lispro, Synachten, TB-500 and GHRP 5

    Judák P, Van Eenoo P, Deventer K · Analytical biochemistry · 2017PubMed Verified

  6. 6.
  7. 7.
    Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry

    Thomas A, Görgens C, Guddat S, Thieme D, Dellanna F, Schänzer W et al. · Journal of separation science · 2016PubMed Verified

  8. 8.
    Solid-phase extraction of small biologically active peptides on cartridges and microelution 96-well plates from human urine

    Semenistaya E, Zvereva I, Krotov G, Rodchenkov G · Drug testing and analysis · 2016PubMed Verified

  9. 9.
    In vitro models for metabolic studies of small peptide hormones in sport drug testing

    Esposito S, Deventer K, Geldof L, Van Eenoo P · Journal of peptide science : an official publication of the European Peptide Society · 2015PubMed Verified

  10. 10.
    Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions

    Thevis M, Thomas A, Schänzer W · Expert review of proteomics · 2014PubMed Verified

  11. 11.
    Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls

    Thevis M, Schänzer W · Journal of pharmaceutical and biomedical analysis · 2014ReviewPubMed Verified

  12. 12.
    Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry

    Kwok WH, Ho EN, Lau MY, Leung GN, Wong AS, Wan TS · Analytical and bioanalytical chemistry · 2013PubMed Verified

  13. 13.
    Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry

    Ho EN, Kwok WH, Lau MY, Wong AS, Wan TS, Lam KK et al. · Journal of chromatography. A · 2012PubMed Verified

  14. 14.
    Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential

    Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P · Drug testing and analysis · 2012PubMed Verified

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice. Many compounds listed are research chemicals not approved for human use. Always consult a qualified healthcare professional before starting any protocol.

Was this page helpful?

Launching soon

Build and track your protocol in Staqk

Log doses, track timing, monitor biomarkers, and manage every compound in your stack — all in one place.

Free early access updates. No spam.